Scientists at the University of Edinburgh have unveiled promising results from the MATCH clinical trial, demonstrating the potential of a…
Read More
A new class of compounds shows promising antibacterial properties, with the potential to aid the fight against antimicrobial resistance.
In a significant development in the global battle against antimicrobial resistance (AMR), an international research collaboration spearheaded by scientists at…
Read More
Groundbreaking Stem Cell Therapy Shows Promise in Reversing Type 1 Diabetes in Mice, Offering New Hope for Patients
Scientists from Stockholm, Sweden, affiliated with Karolinska Institutet and KTH Royal Institute of Technology, have reported a significant advancement in…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Novel Stem Cell Therapy Protocol Shows Significant Promise for Type 1 Diabetes Treatment, Reversing Disease in Mice.
Scientists at the forefront of regenerative medicine, based at the esteemed Karolinska Institutet and KTH Royal Institute of Technology in…
Read More
A Blood Filter Shows Promise in Extending Pregnancies Affected by Preeclampsia
A groundbreaking, albeit small-scale, clinical trial has offered a glimmer of hope for pregnant individuals battling preeclampsia, a serious and…
Read More
OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…
Read More
Piracicaba River Found to Contain Multiple Antibiotic Classes, Accumulating in Fish, Aquatic Plant Shows Mixed Remediation Potential
Researchers from the Center for Nuclear Energy in Agriculture at the University of São Paulo (CENA-USP) have identified multiple classes…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…
Read More
Novo Nordisk’s New Weight Loss Treatment CagriSema Shows Inferiority to Lilly’s Tirzepatide in Head-to-Head Trial
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its eagerly anticipated weight loss treatment,…
Read MoreYOU MAY HAVE MISSED
